Show Notes
Pat Brown is a Senior Clinical Trial Physician in Hematology Clinical Development at the pharmaceutical company Bristol Myers Squibb. (For listeners who aren't familiar with the word hematology, it means the study of blood and blood disorders.)
Pat earned a bachelor’s degree in engineering from the United States Military Academy in West Point, NY, and a master’s degree in philosophy and politics from Oxford University in England. He then went on to get his medical degree from Medical University of South Carolina College of Medicine and then completed his internship and residency training in pediatrics at Johns Hopkins Hospital, followed by completion of fellowship training in pediatrics hematology/oncology in the joint Johns Hopkins/National Cancer Institute program. He joined the Johns Hopkins faculty as an instructor, and was then promoted to assistant, associate, and full professor of oncology and pediatrics and the director of the Pediatric Leukemia Program at the Sidney Kimmel Comprehensive Cancer Center, with a focus on childhood leukemia, which is a cancer of the blood and bone marrow. During his time at Hopkins, Pat has mentored many students who went on to impactful careers in academic and industry, and was honored for his teaching by several awards and being selected to teach for the premiere national board review course for pediatric hematology/oncology.
His lab found that a gene called FLT3 (which was initially discovered by Dr. Brown's mentor, Dr. Don Small) is especially important in certain kinds of childhood leukemia that are especially hard to cure. His lab also identified and helped develop promising combinations of standard chemotherapy drugs and FLT3 inhibitors that can work together to more effectively kill leukemia cells.
Episode highlights:
*Susan introduces Pat [0:56]; *Pat gives an overview of leukemia — what is it? And how does it help us understand other cancers? [3:36]; *Pat explains how DNA mutations lead to cancer, and how those same mutations guide scientists to discover targeted cancer therapies [6:12] Hosted on Acast. See acast.com/privacy for more information.
More from Science Fare
In this mini episode, Dr. Jonathan Bogan explains how insulin triggers the TUG protein to help move GLUT 4 transporter proteins from inside the cell to the cell membrane. There, they transport glucose from the bloodstream into the cell using facilitated diffusion. Tune in next week for the full-length interview. Hosted on Acast. See acast.com/privacy for more information.
Dr. Dina Simkin is an Research Assistant Professor at Northwestern University's Feinberg School of Medicine whose research mainly focuses on how on how mutations in ion channel proteins contribute to pediatric epilepsy and neurodevelopmental disorders. Dr. Simkin earned her BS in Biochemistry, and then proceeded to earn PhDs in Neuroscience, Biophysics, and in Cellular and Molecular Pharmacology. She additionally completed post-graduate training in both the neurophysiology of aging and stem cell-derived neuronal models of epileptic channelopathy.
In this mini episode, Dr. Dina Simkin tells us how she uses CRISPR to do more elegant experiments for her work on ion channels. Tune in next week for the full-length interview. Hosted on Acast. See acast.com/privacy for more information.
Lydia Pecker, M.D., is a pediatric hematologist and director of research and advocacy at the Sickle Cell Center for Adults at Johns Hopkins University. She previously served as the founding director of the Center's Young Adult Clinic, which was built to support young people transitioning from pediatric to adult care systems. She received her undergraduate degree in Africana studies from Brown University, earned her M.D. at the University of Pennsylvania School of Medicine, and received a Master's degree in Health Sciences from the Bloomberg School of Public Health.
In this mini episode, Dr. Lydia Pecker explains the complexity in real-life sickle cell inheritance patterns. Tune in next week for the full-length interview. Hosted on Acast. See acast.com/privacy for more information.